Ovarian Cancer Coverage from Every Angle

SGO 2019: Niraparib Maintenance and Quality of Life in Recurrent Ovarian Cancer

By: Melissa E. Fryman, MS
Posted: Tuesday, March 26, 2019

Niraparib maintenance can maintain remission and prolong the time without symptoms or toxicities (TWiST) experienced by patients with platinum-sensitive recurrent ovarian cancer. Ursula A. Matulonis, MD, of the Dana-Farber Cancer Institute, Boston, and colleagues previously found that maintenance treatment with the PARP inhibitor niraparib in this patient population could improve progression-free survival without significantly decreasing quality of life, compared with placebo. Here, they quantified the mean duration of toxicity and symptom-free benefit. The TWiST analysis results of the ENGOT24-OV16/NOVA trial were presented during the Plenary Session at the 2019 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer in Honolulu (Abstract 1).

In this phase III, double-blind trial, 553 women with platinum-sensitive recurrent ovarian cancer were randomly assigned to receive niraparib or placebo. Patients had either germline BRCA mutations or high-grade serous cancer and were followed until disease progression. TWiST was estimated as the difference between progression-free-survival and mean toxicity time, which was defined as the number of days with symptomatic adverse events (classified as grade 2 or greater fatigue, nausea, and vomiting). The mean TWiST benefit for niraparib-treated patients, compared with placebo, was 2.95 years (for those with germline BRCA mutations) and 1.34 years (for those with high-grade serous cancer).

“It’s really important to demonstrate that, if we’re adding a maintenance therapy, we’re not significantly altering women’s quality of life,” emphasized Dr. Matulonis in an SGO press release. “They now have the option to prolong their progression-free survival with a PARP inhibitor.” The ultimate goal, she said, should be to avoid unacceptable toxicities while keeping cancer in remission.

Disclosure: The study authors’ disclosure information may be found at sgo.confex.com.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.